Navigation Links
GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting
Date:8/27/2010

ATLANTA, Aug. 27 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced the results of its Annual Shareholders Meeting, held on August 24, 2010.

During the meeting, shareholders re-elected seven nominees for directors of the company to serve until the 2011 Annual Meeting of Shareholders and until their successors are duly elected or appointed and qualified. They are:

  • Donald G. Hildebrand, Chairman of the Board of Directors
  • Robert T. McNally, Ph.D., President and CEO
  • Harriet L. Robinson, Ph.D., Chief Scientific Officer
  • Steven S. Antebi, Independent Director
  • David A. Dodd, Independent Director
  • Dean G. Kollintzas, Independent Director
  • John N. Spencer, Jr., CPA, Independent Director

  • Additionally, stockholders ratified the appointment of Porter Keadle Moore LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2010.

    Don Hildebrand, company co-founder and Chairman of the Board of Directors, provided opening remarks and conducted the formal business of the meeting.

    In addition to the business of the annual meeting, Robert McNally, president and chief executive officer, provided an overview of the company's progress, highlighting GeoVax's performance since the last annual meeting held in June 2009. He discussed significant scientific outreach including conferences where GeoVax participated in presenting advances in vaccine development, and improvement in corporate communications through a new public and investor relations firm, IRG.  Dr. Harriet Robinson, company CSO, discussed clinical and research progress including the current status of the Phase 2a Preventative Vaccine Trial including the expansion from 225 to 300 participants.  She also indicated the screening of the Therapeutic Trial volunteers is on target to begin generating vaccine safety and performance data during 2011, with trial completion within 24 to 36 months.  Mark Reynolds, chief financial officer, provided a financial update and discussed the Company's sources of capital.

    HIV/AIDS BackgroundHIV affects the entire globe and comes in a variety of subtypes. Clade B is the predominant subtype in North America where there are roughly 60,000 new infections each year. Globally, there are about 2.5 million AIDS infections per year, most primarily involving subtypes AG, B, and C. In 2007, UNAIDS reported 1.3 million people living with AIDS in North America and 33.2 million people living with AIDS worldwide. Presently, there is little to prevent HIV transmission other than education, circumcision, and condoms. It is obvious from the spread of the disease that these methods are not adequate. Existing treatments for individuals infected with HIV include anti-retroviral therapies that are effective but have serious medical side effects and are very expensive (upwards of $1,500/month). This cost is borne primarily by the individual and sometimes by third party insurance, local healthcare, federal or world health organizations. Development and distribution of an effective HIV/AIDS vaccine holds great promise. The GeoVax vaccine would cost a fraction of the cost of current treatments and, to date, has not elicited serious adverse side effects in several human trials. A population vaccinated with an effective HIV-1 vaccine would be expected to significantly decrease the prevalence of AIDS over time.

    About GeoVax Labs, Inc.GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, oversee manufacturing and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV immune responses, as well as the vaccines' safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Recently the FDA granted permission to proceed with a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit www.geovax.com.

    Forward-Looking Statements

    Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.Contact:At the Company:Robert McNally, President & CEO(678) 384-7220 or rmcnally@geovax.comAt The Investor Relations Group:Investor RelationsJames CarbonaraorPublic RelationsJanet Vasquez / Robin O'Malley(212) 825-3210
    '/>"/>

    SOURCE GeoVax Labs, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
    2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
    3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
    4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
    5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
    6. GeoVax to Present at the BIO CEO & Investor Conference 2009
    7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
    8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
    9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
    10. GeoVax Labs, Inc. Announces First Quarter Financial Results
    11. GeoVax to Exhibit at the 2009 BIO International Convention
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
    (Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
    (Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
    (Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
    Breaking Biology Technology:
    (Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
    (Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
    (Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
    Breaking Biology News(10 mins):